CN115151540B - 作为mettl3抑制剂的多杂环化合物 - Google Patents
作为mettl3抑制剂的多杂环化合物Info
- Publication number
- CN115151540B CN115151540B CN202080095149.6A CN202080095149A CN115151540B CN 115151540 B CN115151540 B CN 115151540B CN 202080095149 A CN202080095149 A CN 202080095149A CN 115151540 B CN115151540 B CN 115151540B
- Authority
- CN
- China
- Prior art keywords
- methyl
- indol
- oxo
- carboxamide
- pyrido
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D497/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D497/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D497/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1917603.1A GB201917603D0 (en) | 2019-12-02 | 2019-12-02 | Inhibitory compounds |
| GB1917603.1 | 2019-12-02 | ||
| GBGB2015692.3A GB202015692D0 (en) | 2020-10-02 | 2020-10-02 | Inhibitory compounds |
| GB2015692.3 | 2020-10-02 | ||
| GB2015820.0 | 2020-10-06 | ||
| GBGB2015820.0A GB202015820D0 (en) | 2020-10-06 | 2020-10-06 | Inhibitory compounds |
| PCT/GB2020/053081 WO2021111124A1 (en) | 2019-12-02 | 2020-12-01 | Polyheterocyclic compounds as mettl3 inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115151540A CN115151540A (zh) | 2022-10-04 |
| CN115151540B true CN115151540B (zh) | 2026-07-31 |
Family
ID=73854829
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202080095149.6A Active CN115151540B (zh) | 2019-12-02 | 2020-12-01 | 作为mettl3抑制剂的多杂环化合物 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US12195458B2 (enExample) |
| EP (1) | EP4069694A1 (enExample) |
| JP (2) | JP7765088B2 (enExample) |
| KR (1) | KR102962548B1 (enExample) |
| CN (1) | CN115151540B (enExample) |
| AU (1) | AU2020394867A1 (enExample) |
| BR (1) | BR112022010561A2 (enExample) |
| CA (1) | CA3162166A1 (enExample) |
| IL (1) | IL293340B1 (enExample) |
| MX (1) | MX2022006700A (enExample) |
| WO (1) | WO2021111124A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020201773A1 (en) * | 2019-04-05 | 2020-10-08 | Storm Therapeutics Ltd | Mettl3 inhibitory compounds |
| US12195458B2 (en) | 2019-12-02 | 2025-01-14 | Storm Therapeutics Limited | Polyheterocyclic compounds as METTL3 inhibitors |
| WO2022074379A1 (en) * | 2020-10-06 | 2022-04-14 | Storm Therapeutics Limited | Mettl3 inhibitory compounds |
| GB202107907D0 (en) * | 2021-06-02 | 2021-07-14 | Storm Therapeutics Ltd | Combination therapies |
| GB202107905D0 (en) * | 2021-06-02 | 2021-07-14 | Storm Therapeutics Ltd | Processes for the preparation of inhibitory compounds |
| CN115894447B (zh) * | 2021-09-22 | 2024-10-01 | 成都先导药物开发股份有限公司 | Mettl3抑制剂及其用途 |
| CN116514805A (zh) * | 2021-12-10 | 2023-08-01 | 成都先导药物开发股份有限公司 | Mettl3抑制剂化合物 |
| WO2023129933A2 (en) * | 2021-12-29 | 2023-07-06 | 858 Therapeutics, Inc. | 6,6-fused heterocyclic compounds as mettl3 inhibitors |
| WO2023151697A1 (zh) | 2022-02-11 | 2023-08-17 | 四川海思科制药有限公司 | 一种mettl3抑制剂及组合物及其在医药上的应用 |
| WO2023235756A1 (en) * | 2022-05-31 | 2023-12-07 | The Trustees Of The University Of Pennsylvania | Compounds for the treatment of hiv |
| JP2025530847A (ja) * | 2022-09-16 | 2025-09-17 | 北京華益健康薬物研究中心 | Ｍｅｔｔｌ３阻害剤化合物、その医薬組成物及び用途 |
| GB202218672D0 (en) | 2022-12-12 | 2023-01-25 | Storm Therapeutics Ltd | Inhibitory compounds |
| EP4652163A1 (en) | 2023-01-20 | 2025-11-26 | Epics Therapeutics | Piperidine derivatives as mettl3 inhibitors |
| JP2026514449A (ja) | 2023-03-30 | 2026-05-11 | ノヴァリックス | 新規ｍｅｔｔｌ３阻害剤及び治療におけるその使用 |
| CN119899188A (zh) * | 2023-10-26 | 2025-04-29 | 杭州邦顺制药有限公司 | Mettl3抑制剂 |
| GB202316595D0 (en) | 2023-10-30 | 2023-12-13 | Storm Therapeutics Ltd | Inhibitory compounds |
| GB202316683D0 (en) | 2023-10-31 | 2023-12-13 | Storm Therapeutics Ltd | Inhibitory compounds |
| IT202400011764A1 (it) | 2024-05-23 | 2025-11-23 | Storm Therapeutics Ltd | Processi per la preparazione di composti inibitori |
| CN121735955A (zh) * | 2024-09-25 | 2026-03-27 | 中国科学院上海药物研究所 | 稠合双环类化合物及其制备方法、组合物和应用 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107349217A (zh) * | 2017-07-21 | 2017-11-17 | 深圳大学 | 一种基于mettl3的小干扰rna及其药物和应用 |
Family Cites Families (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5753664A (en) * | 1995-03-16 | 1998-05-19 | Takeda Chemical Industries, Ltd. | Heterocyclic compounds, their production and use |
| FR2734814B1 (fr) | 1995-05-31 | 1997-07-04 | Adir | Nouveaux composes alkoxy-aryles, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| CA2242425C (en) | 1996-02-13 | 2006-07-18 | Zeneca Limited | Quinazoline derivatives as vegf inhibitors |
| NZ331191A (en) | 1996-03-05 | 2000-03-27 | Zeneca Ltd | 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof |
| US5928323A (en) | 1996-05-30 | 1999-07-27 | Sun Microsystems, Inc. | Apparatus and method for dynamically generating information with server-side software objects |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| BR9808398A (pt) | 1997-03-21 | 2000-05-16 | Novartis Ag | Derivados pirazol com atividade herbicida |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| FR2783519B1 (fr) | 1998-09-23 | 2003-01-24 | Sod Conseils Rech Applic | Nouveaux derives d'amidines, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les contenant |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| EE05345B1 (et) | 1999-02-10 | 2010-10-15 | Astrazeneca Ab | Kinasoliini derivaadid angiogeneesi inhibiitoritena |
| BR0111230A (pt) | 2000-05-31 | 2003-06-10 | Astrazeneca Ab | Composto, e, uso e processo para a preparação do mesmo |
| UA73993C2 (uk) | 2000-06-06 | 2005-10-17 | Астразенека Аб | Хіназолінові похідні для лікування пухлин та фармацевтична композиція |
| EE200300015A (et) | 2000-07-07 | 2004-10-15 | Angiogene Pharmaceuticals Limited | Kolhinooli derivaadid kui angiogeneesi inhibiitorid |
| KR20030014425A (ko) | 2000-07-07 | 2003-02-17 | 앤지오젠 파마슈티칼스 리미티드 | 혈관 손상제인 콜치놀 유도체 |
| JP2004531471A (ja) | 2000-12-21 | 2004-10-14 | グラクソ グループ リミテッド | マクロライド抗生物質 |
| CA2438318A1 (en) | 2001-02-16 | 2002-08-29 | Aventis Pharmaceuticals Inc. | Novel heterocyclic amide derivatives and their use as dopamine d3 receptor ligands |
| US7169795B2 (en) | 2003-09-30 | 2007-01-30 | Bristol Myers Squibb Company | Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors |
| US20050261201A1 (en) | 2004-03-30 | 2005-11-24 | Rejuvenon Corporation | Method of reducing C-reactive protein using growth hormone secretagogues |
| TW200700387A (en) | 2005-03-21 | 2007-01-01 | Akzo Nobel Nv | 1-benzylindole-2-carboxamide derivatives |
| MX2007015772A (es) | 2005-06-17 | 2008-02-22 | Wyeth Corp | Compuestos utiles como inhibidores de serotonina y agonistas y antagonistas de 5-ht-1a. |
| JP5094725B2 (ja) | 2005-10-04 | 2012-12-12 | イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・エルレ・エルレ | Ｈｉｖインテグラーゼ阻害剤 |
| HRP20100194T8 (hr) | 2005-10-21 | 2010-06-30 | Glaxo Group Limited | Perikondenzirani triciklički spojevi, korisni kao antibakterijska sredstva |
| US8247556B2 (en) * | 2005-10-21 | 2012-08-21 | Amgen Inc. | Method for preparing 6-substituted-7-aza-indoles |
| CN102633783A (zh) | 2006-02-10 | 2012-08-15 | 转化技术制药公司 | 作为Aurora激酶抑制剂的苯并唑系衍生物、组合物和使用方法 |
| JP5415942B2 (ja) | 2006-06-22 | 2014-02-12 | プラナ バイオテクノロジー リミティッド | 処置の方法およびその処置に有用な薬剤 |
| WO2008016666A2 (en) | 2006-08-02 | 2008-02-07 | Cytokinetics, Incorporated | Certain chemical entities, compositions, and methods |
| ES2420479T3 (es) * | 2006-08-31 | 2013-08-23 | Sk Chemicals, Co., Ltd. | Procedimiento para la producción de microesferas cargadas con fármacos y microesferas cargadas con fármacos producidas mediante el mismo |
| WO2008074068A1 (en) | 2006-12-20 | 2008-06-26 | Prana Biotechnology Limited | Substituted quinoline derivatives as antiamyloidogeneic agents |
| AR064517A1 (es) | 2006-12-22 | 2009-04-08 | Avexa Ltd | Pirimidinionas biciclicas y sus usos |
| CN101636398A (zh) * | 2007-02-05 | 2010-01-27 | 泽农医药公司 | 用于治疗钠通道介导的疾病或疾病状态的吡啶并嘧啶酮化合物 |
| KR20090112720A (ko) | 2007-02-13 | 2009-10-28 | 헬신 세라퓨틱스 (유.에스.) 인크. | 성장 호르몬 분비촉진제를 이용한 세포 증식 질환의 치료방법 |
| EP2178870B1 (en) | 2007-08-17 | 2018-09-19 | LG Chem, Ltd. | Indole and indazole compounds as an inhibitor of cellular necrosis |
| US8536221B2 (en) | 2008-02-07 | 2013-09-17 | Abbvie Inc. | Amide derivatives as positive allosteric modulators and methods of use thereof |
| ES2392796T3 (es) * | 2008-04-17 | 2012-12-13 | Proximagen Limited | Moduladores de tipo indol del receptor nicotínico de acetilcolina alfa-7 |
| MX2010013399A (es) * | 2008-06-06 | 2010-12-21 | Abbott Lab | Nuevos compuestos de 1,2,4-oxadiazol y sus metodos de uso. |
| US8318732B2 (en) | 2008-07-02 | 2012-11-27 | Avexa Limited | Compounds having antiviral properties |
| EP2247601B1 (en) | 2008-07-02 | 2013-04-10 | Avexa Limited | Thiazopyrimidinones and uses thereof |
| WO2010000031A1 (en) | 2008-07-02 | 2010-01-07 | Avexa Limited | Imidazopyrimidinones and uses thereof |
| CN101628913B (zh) | 2008-07-18 | 2013-01-23 | 中国科学院广州生物医药与健康研究院 | 用作雌激素相关受体调节剂的化合物及其应用 |
| UY32138A (es) * | 2008-09-25 | 2010-04-30 | Boehringer Ingelheim Int | Amidas sustituidas del ácido 2-(2,6-dicloro-fenilamino)-6-fluoro-1-metil-1h-bencimidazol-5-carboxílico y sus sales farmacéuticamente aceptables |
| WO2010074101A1 (ja) * | 2008-12-25 | 2010-07-01 | 住友化学株式会社 | アミノピリジン化合物及びその用途 |
| WO2010114898A1 (en) | 2009-03-31 | 2010-10-07 | Arqule, Inc. | Substituted dipyrido-pyrimido-diazepine and benzo-pyrido-pyrimido compounds |
| US9040568B2 (en) | 2009-05-29 | 2015-05-26 | Abbvie Inc. | Pharmaceutical compositions for the treatment of pain |
| WO2011050245A1 (en) | 2009-10-23 | 2011-04-28 | Yangbo Feng | Bicyclic heteroaryls as kinase inhibitors |
| CN102336751A (zh) | 2010-07-16 | 2012-02-01 | 爱维艾珂瑟有限公司 | 新型抗病毒剂 |
| WO2012129562A2 (en) | 2011-03-24 | 2012-09-27 | The Scripps Research Institute | Compounds and methods for inducing chondrogenesis |
| TW201245185A (en) | 2011-04-01 | 2012-11-16 | Lundbeck & Co As H | New positive allosteric modulators of nicotinic acetylcholine receptor |
| EP3406252B1 (en) | 2012-02-10 | 2020-05-13 | PTC Therapeutics, Inc. | Compounds for treating spinal muscular atrophy |
| WO2014063199A1 (en) | 2012-10-26 | 2014-05-01 | Akaal Pharma Pty Ltd | Organic compounds |
| WO2014148557A1 (ja) | 2013-03-19 | 2014-09-25 | 凸版印刷株式会社 | Ｅｇｆｒ阻害剤感受性予測方法 |
| WO2015105657A1 (en) * | 2013-12-19 | 2015-07-16 | Ptc Therapeutics, Inc. | Methods for modulating the amount of rna transcripts |
| WO2015192761A1 (zh) | 2014-06-17 | 2015-12-23 | 辰欣药业股份有限公司 | 作为mTOR/PI3K抑制剂的吡啶并[1,2-a]嘧啶酮类似物 |
| CN106470992B (zh) | 2014-06-17 | 2018-11-06 | 正大天晴药业集团股份有限公司 | 作为pi3k抑制剂的吡啶并[1,2-a]嘧啶酮类似物 |
| AR101674A1 (es) | 2014-08-22 | 2017-01-04 | Glaxosmithkline Ip Dev Ltd | Uso de un compuesto tricíclico que contiene nitrógeno |
| WO2016054491A1 (en) | 2014-10-03 | 2016-04-07 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| EP3310169B1 (en) | 2015-05-30 | 2023-05-17 | PTC Therapeutics, Inc. | Methods for modulating rna splicing |
| WO2017070464A1 (en) * | 2015-10-22 | 2017-04-27 | Memorial Sloan-Kettering Cancer Center | Cofactor analogs as methyltransferase inhibitors for treating cancer |
| US10919914B2 (en) | 2016-06-08 | 2021-02-16 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| WO2018053313A1 (en) * | 2016-09-19 | 2018-03-22 | Memorial Sloan-Kettering Cancer Center | Adenosine analogs as methyltransferase inhibitors for treating cancer |
| JP2019535789A (ja) | 2016-11-28 | 2019-12-12 | ピーティーシー セラピューティクス，インコーポレーテッド | Ｒｎａスプライシングを調節する方法 |
| CN110520127B (zh) | 2017-03-26 | 2023-05-16 | 武田药品工业株式会社 | 作为gpr6的调节剂的经哌啶基取代的杂芳族羧酰胺和经哌嗪基取代的杂芳族羧酰胺 |
| EP3589745A1 (en) * | 2018-04-11 | 2020-01-08 | Chemestmed Ltd. | A method of modulating the rna methylation |
| JP7627209B2 (ja) | 2018-08-14 | 2025-02-05 | エピザイム，インコーポレイティド | 置換インドール及びその使用方法 |
| WO2020112872A1 (en) | 2018-11-30 | 2020-06-04 | Epizyme, Inc. | Methods of treating whsc1-overexpressing cancers by inhibiting setd2 |
| CN109674792A (zh) * | 2019-01-23 | 2019-04-26 | 四川大学 | 取代的5,6-二氢异喹啉并[3,2-α]异喹啉-7-鎓衍生物的用途 |
| WO2020201773A1 (en) * | 2019-04-05 | 2020-10-08 | Storm Therapeutics Ltd | Mettl3 inhibitory compounds |
| US12195458B2 (en) | 2019-12-02 | 2025-01-14 | Storm Therapeutics Limited | Polyheterocyclic compounds as METTL3 inhibitors |
-
2020
- 2020-12-01 US US17/778,701 patent/US12195458B2/en active Active
- 2020-12-01 KR KR1020227022463A patent/KR102962548B1/ko active Active
- 2020-12-01 IL IL293340A patent/IL293340B1/en unknown
- 2020-12-01 JP JP2022532865A patent/JP7765088B2/ja active Active
- 2020-12-01 AU AU2020394867A patent/AU2020394867A1/en active Pending
- 2020-12-01 BR BR112022010561A patent/BR112022010561A2/pt unknown
- 2020-12-01 EP EP20825189.2A patent/EP4069694A1/en active Pending
- 2020-12-01 WO PCT/GB2020/053081 patent/WO2021111124A1/en not_active Ceased
- 2020-12-01 CN CN202080095149.6A patent/CN115151540B/zh active Active
- 2020-12-01 MX MX2022006700A patent/MX2022006700A/es unknown
- 2020-12-01 CA CA3162166A patent/CA3162166A1/en active Pending
-
2022
- 2022-07-29 US US17/876,938 patent/US11725010B2/en active Active
-
2024
- 2024-11-01 US US18/934,945 patent/US20250122195A1/en active Pending
-
2025
- 2025-10-17 JP JP2025175449A patent/JP2026027269A/ja active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107349217A (zh) * | 2017-07-21 | 2017-11-17 | 深圳大学 | 一种基于mettl3的小干扰rna及其药物和应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP4069694A1 (en) | 2022-10-12 |
| US20250122195A1 (en) | 2025-04-17 |
| IL293340A (en) | 2022-07-01 |
| CA3162166A1 (en) | 2021-06-10 |
| AU2020394867A1 (en) | 2022-05-26 |
| US20230002378A1 (en) | 2023-01-05 |
| JP2026027269A (ja) | 2026-02-18 |
| US11725010B2 (en) | 2023-08-15 |
| US20230116403A1 (en) | 2023-04-13 |
| WO2021111124A1 (en) | 2021-06-10 |
| KR102962548B1 (ko) | 2026-05-11 |
| MX2022006700A (es) | 2022-09-02 |
| JP2023506147A (ja) | 2023-02-15 |
| US12195458B2 (en) | 2025-01-14 |
| KR20220113431A (ko) | 2022-08-12 |
| JP7765088B2 (ja) | 2025-11-06 |
| IL293340B1 (en) | 2026-05-01 |
| CN115151540A (zh) | 2022-10-04 |
| BR112022010561A2 (pt) | 2022-11-16 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |